Drug watchdog: tracking a leukemia Drug's Real-World impact
NCT ID NCT04307134
Summary
This study monitored the safety and effectiveness of the drug Besponsa in Korean patients with a hard-to-treat form of blood cancer (B-cell ALL). It was a required safety check after the drug was approved for sale, involving 108 patients who received the drug as part of their normal care. The goal was to see how the drug performed and what side effects occurred in everyday medical practice.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.